Literature DB >> 9112017

Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.

H Yokoyama1, O Tomonaga, M Hirayama, A Ishii, M Takeda, T Babazono, U Ujihara, C Takahashi, Y Omori.   

Abstract

A progressive decline in glomerular function occurs in diabetic nephropathy. The predictive effects of progression promoters were examined in 182 non-insulin-dependent diabetic patients from a baseline serum creatinine concentration of 133 mumol/l. During a total of 605 person-years follow-up, 107 patients developed end-stage renal failure requiring dialysis. The rate of decline of renal function was highly variable. Urinary protein excretion was the strongest predictor correlated to the rate of decline, followed by diastolic and systolic blood pressure, total cholesterol and platelet count, while the protective effects were seen in serum albumin and haematocrit. Adjustment for urinary protein excretion revealed that diastolic blood pressure, familial predisposition to hypertension, serum albumin, and smoking were independent significant predictors. Angiotensin converting enzyme inhibitors (ACE-I) significantly retarded the development of end-stage renal failure compared to antihypertensives other than ACE-I (mostly nifedipine), and the effect was evident particularly in patients with proteinuria below the median (2.5 g/24 h) (presumably those who responded to ACE-I). A complex effect of proteinuria in association with blood pressure elevation, familial predisposition to hypertension, hypoalbuminaemia, and smoking may play an important role in the progression of nephropathy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9112017     DOI: 10.1007/s001250050694

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  23 in total

Review 1.  Management of diabetic nephropathy.

Authors:  L Foggensteiner; S Mulroy; J Firth
Journal:  J R Soc Med       Date:  2001-05       Impact factor: 5.344

2.  Circadian Blood Pressure Rhythm Is Changed by Improvement in Hypoalbuminemia and Massive Proteinuria in Patients with Minimal Change Nephrotic Syndrome.

Authors:  Daisaku Ando; Gen Yasuda
Journal:  Cardiorenal Med       Date:  2016-03-01       Impact factor: 2.041

Review 3.  Antihypertensive drugs and diabetic nephropathy.

Authors:  P S Mehler; R W Schrier
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

4.  [Diabetic nephropathy and ACE inhibitors].

Authors:  B Amann
Journal:  Clin Res Cardiol       Date:  2006-01       Impact factor: 5.460

Review 5.  Impact of Lifestyle Modification on Diabetic Kidney Disease.

Authors:  Chijoke Onyenwenyi; Ana C Ricardo
Journal:  Curr Diab Rep       Date:  2015-09       Impact factor: 4.810

Review 6.  The relationship between glucose control and the development and progression of diabetic nephropathy.

Authors:  Carrie A Phillips; Mark E Molitch
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 7.  Anaemia in diabetes: Is there a rationale to TREAT?

Authors:  M C Thomas; M E Cooper; K Rossing; H H Parving
Journal:  Diabetologia       Date:  2006-04-04       Impact factor: 10.122

8.  Determinants of decline in glomerular filtration rate in nonproteinuric subjects with or without diabetes and hypertension.

Authors:  Hiroki Yokoyama; Sakiko Kanno; Suguho Takahashi; Daishiro Yamada; Hiroshi Itoh; Kazumi Saito; Hirohito Sone; Masakazu Haneda
Journal:  Clin J Am Soc Nephrol       Date:  2009-09       Impact factor: 8.237

9.  The Fukuoka Kidney disease Registry (FKR) Study: design and methods.

Authors:  Shigeru Tanaka; Toshiharu Ninomiya; Kiichiro Fujisaki; Hisako Yoshida; Masaharu Nagata; Kosuke Masutani; Masanori Tokumoto; Koji Mitsuiki; Hideki Hirakata; Satoru Fujimi; Yutaka Kiyohara; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  Clin Exp Nephrol       Date:  2016-06-23       Impact factor: 2.801

Review 10.  Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.

Authors:  Vito M Campese
Journal:  Clin Exp Nephrol       Date:  2014-02-18       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.